BCAL Diagnostics Ltd
BDX
Company Profile
Business description
BCAL Diagnostics Ltd is an Australian health care company engaged in early cancer detection. BCAL launched its first test, BREASTESTplus, as a rule-out test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women. BCAL holds an exclusive license with ClearNote Health Inc., a U.S-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Contact
GPO Box Q128
Queen Victoria Building
SydneyNSW1230
AUSSector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
Employees
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,993.00 | 21.60 | 0.24% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,475.10 | 97.53 | 0.19% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,549.85 | 72.04 | 0.27% |
| Nikkei 225 | 64,634.81 | 680.62 | 1.06% |
| NZX 50 Index | 13,725.74 | 34.41 | 0.25% |
| S&P 500 | 7,743.98 | 21.38 | 0.28% |
| S&P/ASX 200 | 8,871.60 | 24.30 | 0.27% |
| SSE Composite Index | 3,681.46 | 0.00 | -0.00% |